{"id":644295,"date":"2026-10-12T17:18:13","date_gmt":"2026-10-12T17:18:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/644295\/"},"modified":"2026-10-12T17:18:13","modified_gmt":"2026-10-12T17:18:13","slug":"nuclide-therapeutics-builds-leaner-radiopharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/644295\/","title":{"rendered":"Nuclide Therapeutics builds leaner radiopharmaceuticals"},"content":{"rendered":"

\u00a0<\/p>\n

At a glance<\/p>\n

Publicly launched: 2024<\/p>\n

Headquarters: London<\/p>\n

Technology: Small-molecule therapeutics and diagnostics containing radioactive halogen isotopes<\/p>\n

Founders: Sofia dos Santos, Richard Edwards, Muhammet Tan\u04ab, and Tim Witney<\/p>\n

Funding or notable partners: \u00a35 million ($6.7 million) from Marathon Beteiligungs and additional investment from undisclosed partners<\/p>\n

The Hercules pub is a special place for the founders of Nuclide Therapeutics (NTx). The watering hole on London\u2019s South Bank is where cofounders Muhammet Tan\u04ab and Tim Witney went to celebrate when they knew they had a special molecule on their hands. They had found a way to inhibit a cancer drug target that had eluded Witney\u2019s lab at King\u2019s College London for years. It\u2019s also where the team headed last year when they shook hands on their first fundraising round<\/a>. The team is using that money to set up its first clinical trial. If all goes well, the founders may toast having dosed their first patient before the end of the year.<\/p>\n

NTx is developing anticancer radiopharmaceuticals<\/a>\u2014specifically theranostics, which are combination regimens that offer both a diagnostic and a therapeutic molecule aimed at the same target. First, the diagnostic molecule binds to cancer cells and emits positrons that enable doctors to image a tumor. Then, the therapeutic molecule delivers cell-killing radiation.<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 At a glance Publicly launched: 2024 Headquarters: London Technology: Small-molecule therapeutics and diagnostics containing radioactive halogen isotopes…\n","protected":false},"author":2,"featured_media":644296,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[1278,142021,114,165,85,46,290044,26624,290041,290042,290046,12365,303,290043,10713,290045,5174],"class_list":["post-644295","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-1278","tag-aldehyde","tag-business","tag-cancer","tag-il","tag-israel","tag-muhammet-tanc","tag-nuclide","tag-radiochemistry","tag-radiopharmaceutical","tag-sofia-dos-santos","tag-start-ups","tag-startups","tag-theranostic","tag-therapeutics","tag-tim-witney","tag-watch"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/644295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=644295"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/644295\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/644296"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=644295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=644295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=644295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}